Apellis Pharmaceuticals (APLS) Short Interest Ratio & Short Volume → Incredible Opportunity to Retire FAST! (From Crypto 101 Media) (Ad) Free APLS Stock Alerts $42.29 -1.61 (-3.67%) (As of 01:46 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Apellis Pharmaceuticals Short Interest DataCurrent Short Volume10,670,000 sharesPrevious Short Volume10,440,000 sharesChange Vs. Previous Month+2.20%Dollar Volume Sold Short$549.51 millionShort Interest Ratio / Days to Cover8.0Last Record DateApril 15, 2024Outstanding Shares121,290,000 sharesPercentage of Shares Shorted8.80%Today's Trading Volume1,463,269 sharesAverage Trading Volume1,571,711 sharesToday's Volume Vs. Average93% Short Selling Apellis Pharmaceuticals ? Sign up to receive the latest short interest report for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatAPLS Short Interest Over TimeAPLS Days to Cover Over TimeAPLS Percentage of Float Shorted Over Time Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide Apellis Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202410,670,000 shares $549.51 million +2.2%N/A8 $51.50 3/31/202410,440,000 shares $613.66 million -1.4%N/A7.1 $58.78 3/15/202410,590,000 shares $600.88 million +5.3%N/A6.7 $56.74 2/29/202410,060,000 shares $623.42 million -2.0%N/A5.1 $61.97 2/15/202410,270,000 shares $694.05 million -3.8%N/A4.9 $67.58 1/31/202410,670,000 shares $675.30 million -11.3%N/A5.1 $63.29 Get the Latest News and Ratings for APLS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/202412,030,000 shares $844.87 million +2.9%N/A5.4 $70.23 12/31/202311,690,000 shares $699.76 million -9.9%N/A5.1 $59.86 12/15/202312,980,000 shares $683.79 million -14.9%N/A5.2 $52.68 11/30/202315,260,000 shares $822.06 million -5.5%N/A6.4 $53.87 11/15/202316,140,000 shares $781.18 million -0.6%N/A6.9 $48.40 10/31/202316,230,000 shares $789.75 million -12.7%N/A5.2 $48.66 10/15/202318,590,000 shares $900.50 million +10.9%N/A4.5 $48.44 9/30/202316,770,000 shares $637.93 million +23.2%N/A3.3 $38.04 9/15/202313,610,000 shares $604.83 million +10.6%N/A2.9 $44.44 8/31/202312,310,000 shares $519.61 million -10.5%N/A2.7 $42.21 8/15/202313,750,000 shares $449.90 million +43.2%N/A3.1 $32.72 7/31/20239,600,000 shares $247.20 million +1.3%N/A2.6 $25.75 7/15/20239,480,000 shares $801.06 million -1.2%N/A3.5 $84.50 6/30/20239,590,000 shares $873.65 million -16.3%N/A6 $91.10 6/15/202311,460,000 shares $1.03 billion +0.9%N/A6.7 $89.60 5/31/202311,360,000 shares $975.26 million +3.3%N/A7 $85.85 5/15/202311,000,000 shares $969.21 million +7.0%N/A5.6 $88.11 4/30/202310,280,000 shares $857.66 million -16.6%N/A5.4 $83.43 4/15/202312,330,000 shares $998.11 million +0.4%N/A6.7 $80.95 3/31/202312,280,000 shares $809.99 million +1.1%N/A7.1 $65.96 3/15/202312,150,000 shares $796.19 million +13.1%N/A7.6 $65.53 2/28/202310,740,000 shares $703.26 million +18.5%N/A7.4 $65.48 2/15/20239,060,000 shares $479.82 million -0.6%N/A6.5 $52.96 1/31/20239,110,000 shares $480.37 million -5.0%N/A6.9 $52.73 1/15/20239,590,000 shares $504.05 million +4.6%N/A7.4 $52.56 12/30/20229,170,000 shares $474.18 million -8.8%N/A7.1 $51.71 12/15/202210,050,000 shares $526.72 million +1.9%N/A6.9 $52.41 11/30/20229,860,000 shares $492.31 million -5.1%N/A6.6 $49.93 11/15/202210,390,000 shares $484.28 million +6.8%N/A6.3 $46.61 10/31/20229,730,000 shares $588.57 million +10.8%N/A6.6 $60.49 10/15/20228,780,000 shares $499.93 million -10.6%N/A6.4 $56.94 9/30/20229,820,000 shares $670.71 million +7.9%N/A6.8 $68.30 9/15/20229,100,000 shares $589.23 million +8.6%N/A6.9 $64.75 8/31/20228,380,000 shares $507.07 million +4.9%N/A6.5 $60.51Incredible Opportunity to Retire FAST! (Ad)A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide APLS Short Interest - Frequently Asked Questions What is Apellis Pharmaceuticals' current short interest? Short interest is the volume of Apellis Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 10,670,000 shares of APLS short. Learn More on Apellis Pharmaceuticals' current short interest. What is a good short interest ratio for Apellis Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. APLS shares currently have a short interest ratio of 8.0. Learn More on Apellis Pharmaceuticals's short interest ratio. Which institutional investors are shorting Apellis Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Apellis Pharmaceuticals: SG Americas Securities LLC, Concourse Financial Group Securities Inc., Simplex Trading LLC, Portman Square Capital LLP, Perceptive Advisors LLC, TIG Advisors LLC, and Harvest Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Apellis Pharmaceuticals' short interest increasing or decreasing? Apellis Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 10,670,000 shares, an increase of 2.2% from the previous total of 10,440,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Apellis Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Apellis Pharmaceuticals: Organon & Co. (4.29%), BridgeBio Pharma, Inc. (10.86%), Ionis Pharmaceuticals, Inc. (7.12%), Madrigal Pharmaceuticals, Inc. (16.02%), Nuvalent, Inc. (20.97%), Alpine Immune Sciences, Inc. (7.23%), Perrigo Company plc (2.88%), Alkermes plc (7.99%), Blueprint Medicines Co. (6.94%), Elanco Animal Health Incorporated (3.14%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Apellis Pharmaceuticals stock? Short selling APLS is an investing strategy that aims to generate trading profit from Apellis Pharmaceuticals as its price is falling. APLS shares are trading down $1.61 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Apellis Pharmaceuticals? A short squeeze for Apellis Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of APLS, which in turn drives the price of the stock up even further. How often is Apellis Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APLS, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: OGN Short Interest Data BBIO Short Interest Data IONS Short Interest Data MDGL Short Interest Data NUVL Short Interest Data ALPN Short Interest Data PRGO Short Interest Data ALKS Short Interest Data BPMC Short Interest Data ELAN Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:APLS) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsThe AI Stock that’s Disrupting Every IndustryStockEarnings